nach oben

best practice onkologie

Erschienen in:

10.08.2022 | Sarkome | CME

Immuntherapie und zielgerichtete Therapie von Gliomen

verfasst von: J.-M. Werner, G. Ceccon, G. R. Fink, Univ.-Prof. Dr. med. N. Galldiks

Erschienen in: best practice onkologie | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Der Erfolg von Immuntherapien bei extrakranialen Tumoren führte zur Entwicklung verschiedener immunvermittelter Ansätze zur Behandlung von Gliomen. So gelang vor kurzem beispielsweise die Herstellung eines mutationsspezifischen Impfstoffs gegen IDH-mutierte (IDH: Isozitratdehydrogenase) Gliome. Weitere immuntherapeutische Ansätze sind T‑Zell-Therapien, die Blockade bestimmter Immuncheckpoints und die Behandlung mit onkolytischen Viren. Zudem scheinen zielgerichtete Therapien bei Gliompatienten mit seltenen molekulargenetischen Veränderungen wie z. B. einer BRAF-Mutation (BRAF: Serin-Threonin-Kinase B‑Raf, „v-Raf murine sarcoma viral oncogene homolog B“) oder NTRK-Gen-Fusion (NTRK: „neurotrophic tyrosine kinase receptor“) wirksam zu sein. Dieser Artikel bietet eine Übersicht über den aktuellen Stand der Therapieoptionen von Gliomen mittels Immuntherapien sowie zielgerichteter Behandlungen.

Ostrom QT, Cioffi G, Waite K et al (2021) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018. Neuro Oncol 23:iii1–iii105PubMedCrossRef

Weller M, Van Den Bent M, Preusser M et al (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18:170–186PubMedCrossRef

Ceccon G, Werner JM, Dunkl V et al (2018) Dabrafenib treatment in a patient with an epithelioid glioblastoma and BRAF V600E mutation. Int J Mol Sci 19:1090PubMedCentralCrossRef

Cordell EC, Alghamri MS, Castro MG et al (2022) T lymphocytes as dynamic regulators of glioma pathobiology. Neuro Oncol. https://doi.org/10.1093/neuonc/noac055

Gonzalez-Tablas Pimenta M, Otero A, Arandia Guzman DA et al (2021) Tumor cell and immune cell profiles in primary human glioblastoma: Impact on patient outcome. Brain Pathol 31:365–380PubMedPubMedCentralCrossRef

Hambardzumyan D, Gutmann DH, Kettenmann H (2016) The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci 19:20–27PubMedPubMedCentralCrossRef

Sampson JH, Gunn MD, Fecci PE et al (2020) Brain immunology and immunotherapy in brain tumours. Nat Rev Cancer 20:12–25PubMedCrossRef

Farhood B, Najafi M, Mortezaee K (2019) CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol 234:8509–8521PubMedCrossRef

Rammensee HG, Loffler MW, Walz JS et al (2020) Tumor vaccines-therapeutic vaccination against cancer. Internist (Berl) 61:690–698CrossRef

10.

Weller M, Roth P, Preusser M et al (2017) Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nat Rev Neurol 13:363–374PubMedCrossRef

11.

Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773PubMedPubMedCentralCrossRef

12.

Schumacher T, Bunse L, Pusch S et al (2014) A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512:324–327PubMedCrossRef

13.

Platten M, Bunse L, Wick A et al (2021) A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature 592:463–468PubMedPubMedCentralCrossRef

14.

Sampson JH, Heimberger AB, Archer GE et al (2010) Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28:4722–4729PubMedPubMedCentralCrossRef

15.

Weller M, Butowski N, Tran DD et al (2017) Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol 18:1373–1385PubMedCrossRef

16.

Bagley SJ, Desai AS, Linette GP et al (2018) CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. Neuro Oncol 20:1429–1438PubMedPubMedCentralCrossRef

17.

Goff SL, Morgan RA, Yang JC et al (2019) Pilot trial of adoptive transfer of chimeric antigen receptor-transduced T cells targeting EGFRvIII in patients with glioblastoma. J Immunother 42:126–135PubMedPubMedCentralCrossRef

18.

Brown CE, Alizadeh D, Starr R et al (2016) Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med 375:2561–2569PubMedPubMedCentralCrossRef

19.

Brown CE, Badie B, Barish ME et al (2015) Bioactivity and safety of IL13Ralpha2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin Cancer Res 21:4062–4072PubMedPubMedCentralCrossRef

20.

Ahmed N, Brawley V, Hegde M et al (2017) HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol 3:1094–1101PubMedPubMedCentralCrossRef

21.

Preusser M, Lim M, Hafler DA et al (2015) Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol 11:504–514PubMedPubMedCentralCrossRef

22.

Jacobs JF, Idema AJ, Bol KF et al (2009) Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro Oncol 11:394–402PubMedPubMedCentralCrossRef

23.

Reardon DA, Brandes AA, Omuro A et al (2020) Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the checkmate 143 phase 3 randomized clinical trial. JAMA Oncol 6:1003–1010PubMedCrossRef

24.

Omuro A, Brandes AA, Carpentier AF et al (2022) Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase 3 trial. Neuro Oncol. https://doi.org/10.1093/neuonc/noac099

25.

Bristol-Myers Squibb (2019) “Bristol-Myers Squibb provides update on phase 3 opdivo (nivolumab) CheckMate-548 trial in patients with newly diagnosed MGMT-methylated glioblastoma multiforme”. Pressemitteilung, 05.09.2019. https://news.bms.com/news/corporate-financial/2019/Bristol-Myers-Squibb-Provides-Update-on-Phase-3-Opdivo-nivolumab-CheckMate--548-Trial-in-Patients-with-Newly-Diagnosed-MGMT-Methylated-Glioblastoma-Multiforme/default.aspx. Zugegriffen: 16. Mai 2022

26.

Nayak L, Standifer N, Dietrich J et al (2022) Circulating immune cell and outcome analysis from the phase 2 study of PD-L1 blockade with durvalumab for newly diagnosed and recurrent glioblastoma. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-21-4064

27.

Brahm CG, Van Linde ME, Enting RH et al (2020) The current status of immune checkpoint inhibitors in neuro-oncology: a systematic review. Cancers (Basel) 12:586CrossRef

28.

Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R et al (2019) Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat Med 25:470–476PubMedCrossRef

29.

Cloughesy TF, Mochizuki AY, Orpilla JR et al (2019) Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med 25:477–486PubMedPubMedCentralCrossRef

30.

Zeng J, Li X, Sander M et al (2021) Oncolytic viro-immunotherapy: an emerging option in the treatment of gliomas. Front Immunol 12:721830PubMedPubMedCentralCrossRef

31.

Cloughesy TF, Petrecca K, Walbert T et al (2020) Effect of vocimagene amiretrorepvec in combination with flucytosine vs standard of care on survival following tumor resection in patients with recurrent high-grade glioma: a randomized clinical trial. JAMA Oncol 6:1939–1946PubMedCrossRef

32.

Desjardins A, Gromeier M, Herndon JE 2nd et al (2018) Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med 379:150–161PubMedPubMedCentralCrossRef

33.

Schindler G, Capper D, Meyer J et al (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121:397–405PubMedCrossRef

34.

Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231–1251PubMedPubMedCentralCrossRef

35.

Komori T (2021) The molecular framework of pediatric-type diffuse gliomas: shifting toward the revision of the WHO classification of tumors of the central nervous system. Brain Tumor Pathol 38:1–3PubMedCrossRef

36.

Behling F, Barrantes-Freer A, Skardelly M et al (2016) Frequency of BRAF V600E mutations in 969 central nervous system neoplasms. Diagn Pathol 11:55PubMedPubMedCentralCrossRef

37.

Korshunov A, Chavez L, Sharma T et al (2018) Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis. Brain Pathol 28:656–662PubMedCrossRef

38.

Wen PY, Stein A, Van Den Bent M et al (2021) Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol 23:53–64PubMedCrossRef

39.

Vaishnavi A, Le AT, Doebele RC (2015) TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov 5:25–34PubMedCrossRef

40.

Drilon A (2019) TRK inhibitors in TRK fusion-positive cancers. Ann Oncol 30:viii23–viii30PubMedPubMedCentralCrossRef

41.

Ferguson SD, Zhou S, Huse JT et al (2018) Targetable gene fusions associate with the IDH wild-type astrocytic lineage in adult gliomas. J Neuropathol Exp Neurol 77:437–442PubMedPubMedCentralCrossRef

42.

Doz F, Van Tilburg CM, Geoerger B et al (2021) Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro Oncol. https://doi.org/10.1093/neuonc/noab274

43.

Persico P, Lorenzi E, Losurdo A et al (2022) Precision oncology in lower-grade gliomas: promises and pitfalls of therapeutic strategies targeting IDH-mutations. Cancers (Basel) 14:1125CrossRef

44.

Dang L, White DW, Gross S et al (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739–744PubMedPubMedCentralCrossRef

45.

Lu C, Ward PS, Kapoor GS et al (2012) IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483:474–478PubMedPubMedCentralCrossRef

46.

Konteatis Z, Artin E, Nicolay B et al (2020) Vorasidenib (AG-881): a first-in-class, brain-penetrant dual inhibitor of mutant IDH1 and 2 for treatment of glioma. ACS Med Chem Lett 11:101–107PubMedPubMedCentralCrossRef

47.

Mellinghoff IK, Penas-Prado M, Peters KB et al (2021) Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; results of a first-in-human phase I trial. Clin Cancer Res 27:4491–4499PubMedPubMedCentralCrossRef

48.

Mellinghoff IK, Ellingson BM, Touat M et al (2020) Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma. J Clin Oncol 38:3398–3406PubMedPubMedCentralCrossRef

49.

Le Rhun E, Preusser M, Roth P et al (2019) Molecular targeted therapy of glioblastoma. Cancer Treat Rev 80:101896PubMedCrossRef

50.

Abou-Elkacem L, Arns S, Brix G et al (2013) Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther 12:1322–1331PubMedCrossRef

51.

Wilhelm SM, Dumas J, Adnane L et al (2011) Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129:245–255PubMedCrossRef

52.

Chen R, Li Q, Xu S et al (2022) Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment. Cancer Cell Int 22:73PubMedPubMedCentralCrossRef

53.

Wong ML, Prawira A, Kaye AH et al (2009) Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas. J Clin Neurosci 16:1119–1130PubMedCrossRef

54.

Lombardi G, De Salvo GL, Brandes AA et al (2019) Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol 20:110–119PubMedCrossRef

55.

Lombardi G, Del Bianco P, Brandes AA et al (2021) Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial). Eur J Cancer 155:179–190PubMedCrossRef

Titel: Immuntherapie und zielgerichtete Therapie von Gliomen
verfasst von: J.-M. Werner
G. Ceccon
G. R. Fink
Univ.-Prof. Dr. med. N. Galldiks
Publikationsdatum: 10.08.2022
Verlag: Springer Medizin
Schlagwörter: Sarkome
Glioblastom
Zielgerichtete Therapie
Gliome
Glioblastom
CAR-T-Zellen
Gliome
Gliome
Glioblastom
Checkpoint-Inhibitoren
Checkpoint-Inhibitoren
Erschienen in: best practice onkologie / Ausgabe 9/2022
Print ISSN: 0946-4565
Elektronische ISSN: 1862-8559
DOI: https://doi.org/10.1007/s11654-022-00422-3

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2022

Einzelfallprüfungen en masse: Ruf nach höherer Bagatellgrenze

Wichtige Studien vom ASCO 2022 – Kolorektales Karzinom

onko-aktuell

Einfluss von Einnahmezeitpunkt und Nahrung auf orale Tumortherapeutika

Strukturierte Befundung in der Radiologie – ein Mehr an Qualität und Transparenz in der onkologischen Diagnostik und Therapie

58/w mit Unterbauchschmerzen, Inappetenz und Völlegefühl